Agile Therapeutics to Present at Needham Healthcare Conference and Pharmaceutical Executive Roundtable
CEO to Provide Insights on the BioPharma Industry and Agile Therapeutics' Commercialization Plans
(firmenpresse) - PRINCETON, NJ -- (Marketwire) -- 03/29/12 -- Agile Therapeutics, a pharmaceutical company focused on developing and commercializing more convenient women's contraceptive products, announced today that Al Altomari, President and Chief Executive Officer, will be presenting at two conferences in the coming weeks: First at the 11th Annual Needham Healthcare Conference, and secondly at the Pharmaceutical Executive roundtable discussion on deal-making.
"I look forward to the opportunity to share my insights on successful deal-making and commercialization strategies at these two key events. As Agile prepares for the commercial launch of our lead product, AG200-15, a once-weekly, low-dose contraceptive patch, we are planning to employ the most effective and efficient approaches for bringing breakthrough products to market," said Mr. Altomari.
Mr. Altomari will speak at the Needham Healthcare Conference on Tuesday, April 3 at 11:40 am ET. A link to the webcast of his presentation will be available at for 90 days following the event. During his presentation, Mr. Altomari will discuss Agile Therapeutics' strategy for growth as it prepares for its first commercial launch and enters the contraceptive market.
Mr. Altomari will also offer his insights on deal-making in pharma and biotech as a panelist at Pharmaceutical Executive's roundtable discussion. This event will take place on April 10th at the Yankee Stadium executive boardroom in New York.
Agile recently completed Phase III clinical trials on a low-dose contraceptive patch and plans to submit its NDA to the U.S, Food and Drug Administration within the next couple of weeks.
Agile Therapeutics is a pharmaceutical development company specializing in women's healthcare products, with an initial focus on providing women with more options and more convenient methods of hormonal contraception. The company's lead product, AG200-15, is a once-weekly contraceptive patch that recently completed Phase III clinical trials. In addition, Agile is also developing a low dose, progestin-only contraceptive patch, AG890. Both AG200-15 and AG890 incorporate proprietary transdermal delivery technology, Skinfusion™, developed by Agile, consisting of an active and peripheral adhesive system that allows stable drug delivery and dependable adhesion over seven days. For more information, please visit .
Needham & Company's 11th Annual Healthcare Conference, to be held in New York April 3rd through 4th, is a high-impact forum for institutional investors and venture capital firms to hear the latest updates from senior management teams of both public and private companies in the Biotechnology, Specialty Pharmaceuticals, Medical Technology and Diagnostics sectors. Over the course of two days, attendees can attend company presentations, as well as expert sessions with clinical and industry professionals.
Pharmaceutical Executive is a monthly publication covering issues and personalities that shape the drug, vaccines and biotech sector. The April 10th roundtable will focus on the state of the environment for deal-making in pharma and biotech. The event is being held in part to highlight annual survey research that the Campbell Alliance Company conducts on trends in this area, including M&A activity, expectations for in-house business development teams, and the most promising therapeutic options for licensing.
:
Chantal Beaudry or Karen Famighetti
for Agile Therapeutics
212-867-1762
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 29.03.2012 - 09:39 Uhr
Sprache: Deutsch
News-ID 1097990
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
PRINCETON, NJ
Phone:
Kategorie:
Drugs
Anmerkungen:
Diese Pressemitteilung wurde bisher 133 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Agile Therapeutics to Present at Needham Healthcare Conference and Pharmaceutical Executive Roundtable
"
steht unter der journalistisch-redaktionellen Verantwortung von
Agile Therapeutics (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
